RESEARCH ARTICLE

Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study

José Abraão Carneiro Neto1, Cássius José Vitor de Oliveira1, Sheila Nunes Ferraz1, Mariele Guerra2, Lívia Alves Oliveira2, Lúcia Passos3, Edgar M. Carvalho1,2,3,4*, Paulo Novis Rocha1,5

1 Post Graduate Program of Health Sciences, Federal University of Bahia, Salvador, Bahia, Brazil, 2 Immunology Service of University Hospital Professor Edgard Santos, Federal University of Bahia, Salvador, Bahia, Brazil, 3 Gonçalo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil, 4 National Institute of Science and Technology of Tropical Diseases, Salvador, Bahia, Brazil, 5 Nephrology Service of University Hospital Professor Edgard Santos, Federal University of Bahia, Salvador, Bahia, Brazil

* imuno@ufba.br

Abstract

Background

While bladder dysfunction is observed in the majority of patients with human T cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM), it is also observed in patients who do not fulfill all diagnostic criteria for HAM. These patients are classified as having possible or probable HAM/TSP. However, it remains unclear whether the severity and progression of bladder dysfunction occurs similarly between these two groups.

Objective

Compare the severity and evolution of bladder dysfunction in HTLV-1-infected patients with possible and definite HAM/TSP.

Methods

The present prospective cohort study followed 90 HTLV-1 patients with possible HAM/TSP and 84 with definite HAM/TSP between April 2011 and February 2019. Bladder dysfunction was evaluated by bladder diary, overactive bladder symptoms scores (OABSS) and urodynamic studies. Bladder dysfunction progression was defined as the need for clean self-intermittent catheterization (CIC).

Results

At baseline, nocturia, urgency and OABSS scores were worse in definite compared to possible HAM/TSP patients. The main urodynamic finding was detrusor overactivity, present in 77.8% of the patients with definite HAM/TSP versus 58.7% of those with possible HAM/TSP (P = 0.05). Upon study conclusion, the cumulative frequency of patients requiring CIC increased in both groups, from 2 to 6 in possible HAM/TSP and from 28 to 44 in definite
HAM/TSP patients. The estimated time to need for CIC was 6.7 years (95%CI 6.5–7.0) in the possible HAM/TSP group compared to 5.5 years (95%CI 4.8–6.1) in the definite HAM/TSP group.

Conclusions

Although both groups showed similarities in bladder dysfunction and tended to progress to requiring CIC over time, patients with possible HAM/TSP presented less severe manifestations at baseline and progressed more slowly than those with definite HAM/TSP.

Author summary

The present prospective cohort study followed 90 HTLV-1 patients with possible HAM/TSP and 84 with definite HAM/TSP between April 2011 and February 2019. Bladder dysfunction was evaluated by bladder diary, overactive bladder symptoms scores (OABSS) and urodynamic studies. Bladder dysfunction progression was defined as the need for clean self-intermittent catheterization (CIC). At baseline, nocturia, urgency and OABSS scores were worse in definite compared to possible HAM/TSP patients. The main urodynamic finding was detrusor overactivity, present in 77.8% of the patients with definite HM/TSP versus 58.7% of those with possible HAM/TSP (P = 0.05). Upon study conclusion, the cumulative frequency of patients requiring CIC increased in both groups, from 2 to 6 in possible HAM/TSP and from 28 to 44 in definite HAM/TSP patients. The estimated time to need for CIC was 6.7 years (95%CI 6.5–7.0) in the possible HAM/TSP group compared to 5.5 years (95%CI 4.8–6.1) in the definite HAM/TSP group. Although both groups showed similarities in bladder dysfunction and tended to progress to requiring CIC over time, patients with possible HAM/TSP presented less severe manifestations at baseline and progressed more slowly than those with definite HAM/TSP.

Introduction

The human T cell lymphotropic virus type 1 (HTLV-1) infects 5–10 million people worldwide [1–3]. South and Central America, Japan, Romania, West Africa and Australia have been identified as endemic areas [4]. HTLV-1 is a retrovirus that predominantly infects T lymphocytes [5]. It is the causal agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell Lymphoma/Leukemia [6]. HTLV-1 infection is considered neglected because most affected patients come from low and middle income countries and also due to low morbidity, as less than 5% of patients develop severe forms of disease [7]. However, it has recently been established that a large percentage of HTLV-1-infected subjects may present other diseases or clinical manifestations related to the infection, including sicca syndrome, periodontal disease, HTLV-1-associated arthropathy, uveitis, pulmonary disease and urinary and/or sexual dysfunction [8–11]. While symptoms of overactive bladder (OAB), characterized by nocturia, increased daytime urinary frequency (DUP) and urgency with or without incontinence, are observed in virtually all patients diagnosed with definite HAM/TSP, up to 37% of HTLV-1-infected subjects who do not meet the clinical criteria for definite HAM/TSP also present OAB [12,13]. Individuals who suffer from urinary dysfunction in the absence of motor disability are considered to have possible or probable HAM/TSP [14].
Urinary dysfunction in affected individuals decreases quality of life (QoL) [12,15], increases the risk of urinary tract infection [16] and may lead to kidney injury [17]. Patients with possible and definite HAM/TSP who suffer from urinary manifestations also present higher proviral load and produce comparatively higher levels of proinflammatory cytokines than HTLV-1 carriers without myelopathy [18]. Data in the literature are inconclusive as to whether bladder dysfunction evolves similarly in patients with possible and definite HAM/TSP. Nocturia usually is the initial urinary manifestation most commonly observed in HTLV-1-infected subjects. Thereafter, some patients develop increased DUF, urgency and incontinence; eventually, this may progress to bladder atony/areflexia [19]. However, this clinical course has not been conclusively documented due to a lack of prospective studies evaluating urinary tract dysfunction in association with HTLV-1. Indeed, it is not known if possible HAM/TSP patients with urological symptoms alone suffer from an isolated clinical entity, or whether these individuals will progress to definite HAM/TSP. The present study endeavored to characterize baseline urological manifestations and compare the evolution of bladder dysfunction in a cohort of patients with possible and definite HAM/TSP.

Materials and methods

Ethics statement

All enrolled patients signed an informed consent form, and the study was approved by the Ethics Committee of Federal University of Bahia. Since 2011, patients with storage and voiding symptoms have been recruited to the cohort by attending urologists. Demographic, clinical, neurological and LUTS data were systematically registered in a database. After ruling out urinary tract infection, urodynamic studies were performed in accordance with International Continence Society (ICS) recommendations [20].

Study design and patients

This prospective cohort study was conducted at an outpatient clinic specialized in the care of patients with HTLV-1, located in a tertiary university hospital in Salvador, Bahia-Brazil. The main sources of patient referral to this clinic are blood banks and other specialty clinics within our hospital complex. All patients with HTLV-1 infection detected by ELISA had confirmation by Western blot. For this study, we screened all HTLV-1 patients that presented between April 2011 and February 2019 for the presence of bladder dysfunction. All patients with lower urinary tract symptoms (LUTS) were subjected to urine cultures. Only patients with LUTS and negative urine cultures were considered eligible for inclusion. Exclusion criteria were a previous history of stroke, pelvic or neurological surgery, severe brain trauma or spinal cord injury, other myelopathy, coinfection with HIV, HBV, HCV or HTLV-2, and pregnancy.

The included patients were evaluated twice a year by voiding diary, the overactive bladder symptoms score (OABSS) questionnaire, and physical and laboratorial examinations. DUF, episodes of nocturia and/or incontinence, urinary retention and the use of treatments (anticholinergic drugs, physiotherapy, intradetrusor application of onabotulinumtoxin Type A, or bladder augmentation with catheterizable conduit) were recorded.

Case definition

The diagnostic criteria proposed by Castro-Costa [14] were applied to determine definite HAM/TSP, characterized by an Osame motor disability scale (OMDS) score >1, difficulty or inability to walk, and spasticity. Patients with possible HAM/TSP presented OAB without gait impairment, but could have hyperreflexia and/or a positive Babinski sign [14].
Bladder dysfunction

Bladder dysfunction was defined by the presence of storage or voiding symptoms characterizing OAB or underactive bladder, respectively [11,19,21]. OAB was defined by an urgency to void, with or without incontinence, usually accompanied by frequency and nocturia and mandatory negative urine culture [22,23]. Incomplete bladder emptying was documented by a high post-void residual volume (≥100 ml) measured by echography or by clean self-intermittent catheterization (CIC) [24]. This was considered the main finding to determine the presence of underactive bladder.

Neurological evaluation

Patients were evaluated by a neurologist and, in addition to the OMDS, the expanded disability status scale (EDSS) was also applied.

Urodynamic evaluation

Evaluations were carried out in accordance with the guidelines established by the American Urologic Association/Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU) and ICS recommendations [20,25,26].

Bladder dysfunction progression

The progression of bladder dysfunction was defined as the need for CIC to promote bladder emptying.

Statistical analysis

Continuous data were expressed as mean ± standard deviation (SD) or median and interquartile range (P25–P75). Categorical variables were described using absolute and relative frequencies. Comparisons of continuous variables between the two study groups, possible HAM/TSP and definite HAM/TSP, were performed using the Student’s t-test for independent samples or the Mann-Whitney U test. Categorical variables were compared using the chi square test. Kaplan-Meier survival analyses were employed to compare time elapsed until need for CIC, and survival curves were compared using the log-rank test. Life-table analysis was also performed to identify the number at risk, number of events and number censored in both groups at each timepoint; these data were then added to the Kaplan-Meier survival figures. We adopted a P value < 0.05 to define statistical significance. All statistical analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS) Version 27.

Results

From April 2011 to February 2019, a total of 193 adult HTLV-1 patients with LUTS and negative urine cultures were screened. Of these, 19 patients were excluded for the following reasons: 11 due to incomplete data and 8 due to coinfection with other viruses (5 with HIV, 2 with hepatitis B and C virus, and 1 with HTLV-2). Baseline clinical and demographic data on the remaining 174 patients, stratified into possible and definite HAM/TSP, are shown in Table 1.

No differences were observed among the groups regarding age, gender, self-declared skin color or marital status. The majority of patients in both groups complained of storage symptoms: increased DUF, nocturia and urgency. The mean frequency of nocturia and urgency episodes, as well as OABSS at baseline, were lower in the possible HAM/TSP group compared to the definite HAM/TSP group. The number of patients requiring CIC to promote bladder emptying was significantly higher (P<0.01) in the definite HAM/TSP group.
Urodynamic analysis

Urodynamic studies were carried out in 92/174 HTLV-1-infected patients upon entry in the cohort (Table 2). Detrusor overactivity (DO) was the most common urodynamic finding in both groups, which tended to be more frequent in definite HAM/TSP patients. Detrusor underactivity (DU) was more common in definite compared to possible HAM/TSP patients ($P < 0.001$). The definite HAM/TSP patients also had lower voided volume and tended to have higher post-void residual volume (PVR) as well as increased bladder filling sensation than patients with possible HAM/TSP. No significant differences were seen between the two groups.

Table 1. Baseline Clinical and Demographic Features of HTLV-1 Infected Patients with Possible and Definite HTLV-1 Associated Myelopathy Followed in a Cohort Study.

| Variables | Possible HAM/TSP N = 90 | Definite HAM/TSP N = 84 | P Value |
|-----------|-------------------------|-------------------------|---------|
| Age (mean ± SD), years | 51.3 ± 12.0 | 51.3 ± 13.0 | 1.00 |
| Female sex (%) | 70/90 (77.8) | 64/84 (76.2) | 0.95 |
| Non-caucasian (%) | 79/90 (87.8) | 67/84 (79.8) | 0.22 |
| Education: Less than high school (%) | 81/90 (90.0) | 73/84 (86.9) | 0.69 |
| Married (%) | 54/90 (60.0) | 42/84 (50.0) | 0.24 |
| DUF (mean ± SD) | 7.0 ± 2.7 | 8.1 ± 5.2 | 0.13 |
| No episodes of urgency (mean ± SD) | 2.4 ± 2.1 | 3.9 ± 5.1 | 0.02 |
| No episodes of nocturia (mean ± SD) | 3.0 ± 1.8 | 4.0 ± 2.4 | 0.00 |
| OABSS | 7.8 ± 3.7 | 9.8 ± 3.8 | 0.00 |
| CIC (%) | 2/84 (2.4) | 25/82 (30.5) | 0.00 |
| OMDS (median; P25 –P75) | 0.0 (0.0–0.0) | 5.0 (3.0–7.0) | 0.00 |
| EDSS (median; P25 –P75) | 0.0 (0.0–2.0) | 5.0 (3.0–6.8) | 0.00 |
| Follow-up (mean ± SD), years | 5.2 ± 1.1 | 5.2 ± 1.1 | 0.90 |

Abbreviations: SD: Standard deviation; EDSS: Expanded Disability Status Scale; OMDS: Osame’s Motor Disability Scale; DUF: Daytime Urinary Frequency; OABSS: Overactive Bladder Symptoms Score; CIC: Clean self-intermittent catheterization. For continuous variables, maximum missing data ranged from 5.7% for demographics (follow up) to 13% for clinical variables (OABSS).

https://doi.org/10.1371/journal.pntd.0009772.t001

Table 2. Baseline Urodynamic Findings in a cohort of 92 HTLV-1-Infected Patients; Evaluation of Urinary Manifestations in Patients with Possible and Definite HTLV-1 Associated Myelopathy.

| Variables | Possible HAM/TSP N = 46 | Definite HAM/TSP N = 46 | P Value |
|-----------|-------------------------|-------------------------|---------|
| Bladder filling sensation (%) | | | |
| Normal | 35/46 (76.1) | 21/44 (47.7) | 0.004 |
| Decreased | 6/46 (13.0) | 5/44 (11.4) | |
| Increased | 5/46 (10.9) | 18/44 (40.9) | |
| FBC—mL (mean ± SD) | 353 ± 127 | 330 ± 151 | 0.33 |
| Compliance—mL/cmH2O (mean ± SD) | 50.5 ± 62.2 | 73.3 ± 156.6 | 0.06 |
| DO (% Yes) | 27/46 (58.7) | 35/45 (77.8) | 0.05 |
| VV—mL (mean ± SD) | 265.2 ± 184.8 | 132.8 ± 147.7 | 0.02 |
| PVR—mL (mean ± SD) | 125 ± 175 | 191 ± 156 | 0.07 |
| DU (% Yes) | 6/45 (13.3) | 23/45 (51.1) | 0.001 |
| BOO (% Yes) | 30/44 (68.2) | 21/42 (50.0) | 0.08 |
| Qmax—mL/s (mean ± SD) | 15 ±15 | 9.5 ± 11 | 0.10 |

Abbreviations: FBC: functional bladder capacity; SD: Standard deviation; DO: detrusor overactivity; VV: voiding volume; PVR: post voiding residual volume; DU: detrusor underactivity; BOO: bladder outlet obstruction; Qmax: Maximum flow rate.

https://doi.org/10.1371/journal.pntd.0009772.t002
regarding functional bladder capacity (FBC), compliance, bladder outlet obstruction (BOO) and maximum flow rate (Qmax) during the emptying phase of urodynamic studies.

**Clinical evolution of HTLV-1 infected patients**

Data regarding the absolute frequency of CIC upon study inclusion and during follow-up are shown in [Fig 1](#). In the possible HAM/TSP group, two patients required CIC at baseline, and four additional patients required CIC over time. Of these four patients who experienced urological disease progression, two also presented worsening neurological symptoms and progressed from possible HAM/TSP to definite HAM/TSP during follow up, as documented by clinical findings and OSAME results; of the possible HAM/TSP patients that did not experience urological disease progression, none progressed to definite HAM/TSP during follow up.

Among the definite HAM/TSP patients, 28 required CIC at baseline and 16 additional patients necessitated CIC during follow-up. Kidney injury detected by increase in the creatinine levels and attributed to urinary retention was observed in 3 patients during follow-up. They recovered renal function after foley catheter insertion followed by a switch to CIC.

Kaplan-Meier survival analysis was performed to compare time since cohort admission until need for CIC in both possible and definite HAM/TSP groups. For this analysis, only

Time since cohort admission till need for clean self-intermittent catheterization (CIC) to promote bladder emptying in 131 patients who did not perform CIC at admission.

![Kaplan-Meier Curves of Time to Clean Self-Intermittent Catheterization in Patients with Possible and Definite HAM/TSP.](https://doi.org/10.1371/journal.pntd.0009772.g001)

|                | Possible HAM/TSP | Definite HAM/TSP |
|----------------|------------------|------------------|
| N at Risk (C)  | 75 (0)           | 56 (0)           |
| Events         |  | |
| Possible HAM/TSP | 1 | 1 |
| Definite HAM/TSP | 3 | 5 |

Abbreviations: CIC: clean intermittent catheterization; HAM/TSP: HTLV-1 associated myelopathy/tropical spastic paraparesis; N: number; C: Censored.

**Fig 1.** Kaplan-Meier Curves of Time to Clean Self-Intermittent Catheterization in Patients with Possible and Definite HAM/TSP. Time since cohort admission until need for clean self-intermittent catheterization (CIC) to promote bladder emptying in 131 patients free of CIC upon cohort entry.

https://doi.org/10.1371/journal.pntd.0009772.g001
patients who were free of CIC at baseline were considered. The mean estimated time to CIC was significantly shorter in the definite HAM/TSP group. As shown in Fig 1, the mean estimated time to CIC was 5.5 (95% CI 4.8–6.1) years in the definite HAM/TSP group compared to 6.7 (95% CI 6.5–7.0) years in the possible HAM/TSP group (P <0.001).

Discussion

Recent studies have shown that a large percentage of HTLV-1-infected subjects who do not meet the criteria for definite HAM/TSP suffer from symptoms or diseases related to this viral infection [8,9,27–29]. Spinal cord injury is the main cause of bladder dysfunction in patients with definite HAM/TSP [30]. However, a high percentage of patients without definite HAM/TSP also present urinary complaints characterized mainly by nocturia, urgency, incontinence and a feeling of incomplete bladder emptying [11]. As some HTLV-1 infected patients with definite HAM/TSP initially develop urinary dysfunction prior to presenting neurological symptoms and signs of myelopathy, it has been suggested that OAB or any other bladder disorder may represent an earlier stage of HAM/TSP [19,31,32]. Nonetheless, the lack of prospective studies evaluating urinary dysfunction in HTLV-1 precludes drawing definitive conclusions.

Herein, we showed that LUTS was a common finding in patients with possible and definite HAM/TSP, yet those with definite HAM/TSP exhibited higher basal frequencies of DUF and nocturia, as well as elevated OABSS values and greater need for CIC. Moreover, urodynamic studies revealed that patients with definite HAM/TSP presented not only storage symptoms, but also a higher frequency of urinary retention. These findings indicate that patients with definite HAM/TSP exhibit more exacerbated bladder dysfunction, mainly regarding the voiding function of the bladder. It follows that definite HAM/TSP patients may face a greater risk of upper urinary tract injury. Nonetheless, minor differences were seen in the other urodynamic parameters evaluated between the groups, indicating that urological dysfunction occurs similarly in individuals with possible and definite HAM/TSP.

We hypothesized that the symptoms characteristic of urinary disorders associated with HTLV-1 infection would develop gradually over time, progressing from nocturia to increased DUF, urinary urgency, incontinence and bladder areflexia [19]. Indeed, the number of patients requiring CIC to promote bladder emptying increased during follow-up in both groups, more notably in patients with definite HAM/TSP. Definite HAM/TSP patients exhibit a longstanding and robust inflammatory immune response that may lead to damage in major neural branches, provoking more dramatic consequences, such as loss of voiding function and requiring more invasive treatment, as demonstrated previously by our group [33]. Although the progressive course of voiding dysfunction of patients with definite HAM/TSP had been previously described [21,34], the present cohort extends these findings to patients with possible HAM/TSP.

Findings from urodynamic studies in patients with possible and definite HAM/TSP have been previously reported [22,35]. Herein, our evaluation of a substantial number of individuals revealed similarities in urodynamic findings between these two patient groups, with more marked urinary dysfunction noted in the definitive HAM/TSP group. Thoracic spinal cord involvement with inflammation and the subsequent narrowing of the spinal cord observed in patients with definite HAM/TSP can help explain the motor disability and high frequency of urinary dysfunction observed in these patients. However, our findings indicate that bladder dysfunction precedes motor disability in patients who do not fulfill the criteria for definite HAM/TSP.
Our study presents some limitations, such as the absence of a control group (non-infected patients), the lack of stratification or classification of overactive bladder (dry, wet and/or refractory) and lack of a formal evaluation of clinical variables that may mimic overactive bladder, such as obesity, exercise and drugs (e.g. diuretics). However, our work does offer a detailed description of HTLV-1-associated bladder dysfunction, with well-documented basal urodynamic data, in a robust sample that includes patients diagnosed with possible and definite HAM/TSP.

In summary, both groups showed similarities in bladder dysfunction and tended to progress to requiring CIC over time; however, patients with possible HAM/TSP presented less severe manifestations at baseline and progressed more slowly than those with definite HAM/TSP. Two out of four patients with progression of bladder symptoms also progressed from possible to definite HAM/TSP. Future studies focused on spinal cord findings in these patients could aid in clarifying the pathophysiology of bladder dysfunction.

Acknowledgments
We thank Cristiano Franco and Paulo Lessa for secretarial assistance, as well as the entire Immunology Service of University Hospital Professor Edgard Santos.

Author Contributions
Conceptualization: José Abraão Carneiro Neto, Edgar M. Carvalho.
Data curation: Lúcia Passos.
Formal analysis: Edgar M. Carvalho.
Funding acquisition: Edgar M. Carvalho.
Investigation: José Abraão Carneiro Neto, Cásssius José Vitor de Oliveira, Sheila Nunes Ferraz, Mariele Guerra, Lívia Alves Oliveira, Edgar M. Carvalho.
Methodology: José Abraão Carneiro Neto, Edgar M. Carvalho.
Project administration: Edgar M. Carvalho.
Supervision: Edgar M. Carvalho, Paulo Novis Rocha.
Validation: Edgar M. Carvalho, Paulo Novis Rocha.
Writing – original draft: José Abraão Carneiro Neto, Edgar M. Carvalho, Paulo Novis Rocha.
Writing – review & editing: José Abraão Carneiro Neto, Edgar M. Carvalho, Paulo Novis Rocha.

References
1. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007; 7: 266–281. https://doi.org/10.1016/S1473-3099(07)70081-6 PMID: 17376384
2. Mata EC, Bezerra RM, Proietti Junior AA, Pamplona LK, Gomes LO, Correa VC, et al. HTLV-1/2 prevalence in two Amazonian communities. Journal of virus eradication. England; 2018. pp. 174–178.
3. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012; 3: 1–23. https://doi.org/10.3389/fmicb.2012.00001 PMID: 22275914
4. Champs AP, Passos VM, Barreto SM, Vaz LS, Ribas JG. [HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study]. Rev Soc Bras Med Trop. 2010. https://doi.org/10.1590/S0037-86822010000600013 PMID: 21181020
5. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science (80-) . 2003. https://doi.org/10.1126.science.1080115 PMID: 12589003

6. Gallo RC. Research and discovery of the first human cancer virus, HTLV-1. Best Pract Res Clin Haematol. 2011; 24: 559–565. https://doi.org/10.1016/j.beha.2011.09.012 PMID: 22173231

7. Brant LJ, Cawley C, Davison KL, Taylor GP. Recruiting Individuals Into The Htvl Cohort Study In The United Kingdom: Clinical Findings And Challenges In The First Six Years, 2003 To 2009. Eurosurveillance. 2011. https://doi.org/10.2807/eese.16.46.20017-en PMID: 22150406

8. Caskey MF, Morgan DJ, Porto AF, Giozza SP, Muniz AL, Orge GO, et al. Clinical Manifestations Associated with HTLV Type I Infection: A Cross-Sectional Study. AIDS Res Hum Retroviruses. 2007. https://doi.org/10.1089/aids.2006.0140 PMID: 17411369

9. Poetker SKW, Porto AF, Giozza SP, Muniz AL, Caskey MF, Carvalho EM, et al. Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. J Clin Virol. 2011. https://doi.org/10.1016/j.jcv.2011.02.004 PMID: 21388871

10. Oliveira P, Castro NM, Muniz AL, Tanajura D, Brandão JC, Porto AF, et al. Prevalence of Erectile Dysfunction in HTLV-1-Infected Patients and Its Association With Overactive Bladder. Urology. 2010. https://doi.org/10.1016/j.urology.2009.11.041 PMID: 20189229

11. Castro NM, Rodrigues W, Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary Symptoms Associated with Human T-Cell Lymphotropic Virus Type I Infection: Evidence of Urinary Manifestations in Large Group of HTLV-I Carriers. Urology. 2007; 69: 813–818. https://doi.org/10.1016/j.urology.2007.01.052 PMID: 17482910

12. Diniz MSC, Feldner PC, Castro RA, Sartori MGF, Girão MJBC. Impact of HTLV-I in quality of life and urogynecologic parameters of women with urinary incontinence. Eur J Obstet Gynecol Reprod Biol. 2009. https://doi.org/10.1016/j.ejogrb.2009.07.024 PMID: 19739555

13. Olindo S, Cabre P, Lézin A, Merle H, Saint-Vil M, Signate A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol. 2006; 63: 1560–1566. https://doi.org/10.1001/archneur.63.11.1560 PMID: 17101824

14. De Castro-costa CM, Araújo AOC, Barreto MM, Takayanagi OM, Sohler MP, Silva ELMDA, et al. Proposal for Diagnostic Criteria of Tropical Spastic Paraparesis/HTLV-I-Associated Myelopathy (HAM/TSP). AIDS Res Hum Retroviruses. 2006; 22: 931–935. https://doi.org/10.1089/aids.2006.22.931 PMID: 17067261

15. Andrade R, Tanajura D, Santana D, dos Santos D, Carvalho EM. Association between urinary symptoms and quality of life in HTLV-1 infected subjects without myelopathy. Int Braz J Urol. 2013; 39: 861–866. https://doi.org/10.1590/S1677-5538.IBJU.2013.06.13 PMID: 24456776

16. Rocha PN, Rehem AP, Santana JF, Castro N, Muniz AL, Salgado K, et al. The cause of urinary symptoms among Human T Lymphotrophic Virus Type I (HTLV-I) infected patients: A cross sectional study. BMC Infect Dis. 2007. https://doi.org/10.1186/1471-2334-7-7 PMID: 17352816

17. Santos RFS, Conceição GC, Martins MS, Kraychete A, Penalva MAC, Carvalho EM, et al. Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients. BMC Nephrol. 2017. 18: 1–7. https://doi.org/10.1186/s12882-016-0417-1 PMID: 28049448

18. Santos SB, Oliveira P, Tannus M, Luna T, Souza A, Delavechia T, et al. Immunological and viral features in patients with overactive bladder indicate an early stage of myelopathy. Retrovirology. 2011. https://doi.org/10.1186/1742-4690-8-S1-A116

19. Tannus M, Tanajura D, Sundberg MA, Oliveira P, Castro N, Santos AM. Detrusor areflexia as an end stage of neurogenic bladder in HAM/TSP? Case Rep Med. 2011. https://doi.org/10.1155/2011/289389 PMID: 21541226

20. Schfter W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good Urodynamic Practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourology. 2002; 21: 261–274. https://doi.org/10.1002/nau.10066 PMID: 11948720

21. Mori KI, Noguchi M, Matsuo M, Nomata K, Nakamura T, Kanetake H. Natural course of voiding function in HTLV-1-Infected Patients and Its Association With Overactive Bladder. Neurourol Urodyn. 2002; 217: 3–6. https://doi.org/10.1016/j.jns.2003.08.004 PMID: 14675601

22. Abrams P, Antibi W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourology. 2009. https://doi.org/10.1002/nau.20737 PMID: 19350662

23. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003. https://doi.org/10.1016/s0090-4295(02)02243-4 PMID: 12559262
24. Asimakopulos AD, De Nunzio C, Kocjancic E, Tubaro A, Rosier PF, Finazzi-Agrò E. Measurement of post-void residual urine. Neurourol Urodyn. 2016. https://doi.org/10.1002/nnau.22671 PMID: 25251215

25. Collins CW, Winters JC. AUA/SUFU adult urodynamics guideline: a clinical review. Urol Clin North Am. 2014; 41: 353–62. vii. https://doi.org/10.1016/j.ucl.2014.04.011 PMID: 25063591

26. Winters JC, Dmochowski RR, Goldman HB, Herndon CDA, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012; 188: 2464–2472. https://doi.org/10.1016/j.juro.2012.09.081 PMID: 23098783

27. Silva MTT, Espíndola OM, Leite AC, Lima MA, Schor D, Araújo A. Isolated bladder dysfunction in human T lymphotropic virus type 1 infection: 10 years of follow-up. J Neurol Neurosurg Psychiatry. 2017; 88: 278–279. https://doi.org/10.1136/jnnp-2016-314606 PMID: 27815322

28. Gomelsky A. Editorial Comment. Braz J Phys Ther. 2016. https://doi.org/10.1016/j.bjpt.2016.01.001

29. Leite ACC, Mendonça GAS, Andrade Serpa MJ, Nascimento OJM, Araújo AQC. Neurological manifestations in HTLV-I-infected blood donors. J Neurol Sci. 2003. https://doi.org/10.1016/s0022-510x(03)00179-5 PMID: 12972388

30. Vilchez C, Gonzalez-Reinoso M, Cubbison C, Perez-Then E, Roa P, Martínez A, et al. Atrophy, focal spinal cord lesions and alterations of diffusion tensor imaging (DTI) parameters in asymptomatic virus carriers and patients suffering from human T-lymphotrophic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurovirol. 2014; 20: 583–590. https://doi.org/10.1007/s13365-014-0282-2 PMID: 25227931

31. Leite ACC, Silva MTT, Alamy AH, Afonso CRA, Lima MAD, Andrad-Serpa MJ, et al. Peripheral neuropathy in HTLV-I infected individuals without tropical spastic paraparesis/HTLV-I-associated myelopathy. J Neurol. 2004. https://doi.org/10.1007/s00415-004-0455-7 PMID: 15258793

32. Araújo Ade Q, Alfonso CR, Schor D, Leite AC, de Andrad-Serpa MJ. Clinical and demographic features of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Rio de Janeiro, Brazil. Acta Neurol Scand. 1993.

33. Carneiro Neto JA, Santos SB, Orge GO, Tanajuara D, Passos L, Oliveira CJ, et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Brazilian J Infect Dis. 2018; 22. https://doi.org/10.1016/j.bjid.2017.10.009 PMID: 29462596

34. Iijima N, Yamauchi J, Yagishi N, Araya N, Aratani S, Tanabe K, et al. Clinical course of neurogenic bladder dysfunction in human T—cell leukemia virus type—1—associated myelopathy / tropical spastic paraparesis: a nationwide registry study in Japan. Orphanet J Rare Dis. 2021; 1–10. https://doi.org/10.1186/s13023-020-01625-z PMID: 33388073

35. Walton GW, Kaplan SA. Urinary dysfunction in tropical spastic paraparesis: Preliminary urodynamic survey. J Urol. 1993. https://doi.org/10.1016/s0022-5347(17)35652-5 PMID: 8345613